Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Ranolazine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Ranolazine | hsa00052 | Galactose metabolism | 1.06E-03 | 2 | P06280, O43451 | GLA, MGAM | More | | Ranolazine | hsa00071 | Fatty acid degradation | 2.52E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Ranolazine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Ranolazine | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Ranolazine | hsa00500 | Starch and sucrose metabolism | 7.59E-07 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Ranolazine | hsa00512 | Mucin type O-glycan biosynthesis | 4.86E-02 | 2 | O95395, Q9NY28 | GCNT3, GALNT8 | More | | Ranolazine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Ranolazine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Ranolazine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 1.34E-02 | 2 | P06865, Q9H4F1 | HEXA, ST6GALNAC4 | More | | Ranolazine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.06E-05 | 2 | P40925, P15104 | MDH1, GLUL | More | | Ranolazine | hsa00730 | Thiamine metabolism | 5.31E-07 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | Ranolazine | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | | Ranolazine | hsa00770 | Pantothenate and CoA biosynthesis | 5.15E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Ranolazine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.77E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Ranolazine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Ranolazine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Ranolazine | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Ranolazine | hsa01100 | Metabolic pathways | 3.52E-02 | 23 | P05089, O95455, P21953, P32320, P11766, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, Q08477, P15907, Q9UNP4, P37837, P32321, Q9BPW9, Q9UHY7, P43490, P46976, P06737 | ARG1, TGDS, BCKDHB, CDA, ADH5, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, CYP4F3, ST6GAL1, ST3GAL5, TALDO1, DCTD, DHRS9, ENOPH1, PBEF1, GYG1, PYGL | More | | Ranolazine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Ranolazine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Ranolazine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Ranolazine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Ranolazine | hsa03040 | Spliceosome | 2.16E-04 | 10 | Q14562, O43143, O60508, O75940, O75494, Q07955, Q01130, Q13243, P11142, O75643 | DHX8, DHX15, CDC40, SMNDC1, FUSIP1, SFRS1, SFRS2, SFRS5, HSPA8, ASCC3L1 | More | | Ranolazine | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Ranolazine | hsa04012 | ErbB signaling pathway | 3.69E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | Ranolazine | hsa04014 | Ras signaling pathway | 8.66E-03 | 7 | Q9NRA1, Q13009, P0DP23, P62873, P63218, P50151, P19174 | PDGFC, TIAM1, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Ranolazine | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | | Ranolazine | hsa04062 | Chemokine signaling pathway | 1.59E-03 | 9 | P07948, P19174, P62873, P63218, P50151, Q13009, P14598, P42224, P25963 | LYN, PLCG1, GNB1, GNG5, GNG10, TIAM1, NCF1, STAT1, NFKBIA | More | | Ranolazine | hsa04070 | Phosphatidylinositol signaling system | 1.59E-03 | 5 | P19174, P0DP23, P23743, P49619, P27987 | PLCG1, CALM1, DGKA, DGKG, ITPKB | More | | Ranolazine | hsa04071 | Sphingolipid signaling pathway | 6.08E-04 | 5 | P21453, Q9H228, P01375, Q13362, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, GAB2 | More | | Ranolazine | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | | Ranolazine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Ranolazine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Ranolazine | hsa04141 | Protein processing in endoplasmic reticulum | 8.60E-03 | 6 | P30101, P60604, P11142, P08238, Q9H173, Q9UNL2 | PDIA3, UBE2G2, HSPA8, HSP90AB1, SIL1, SSR3 | More | | Ranolazine | hsa04145 | Phagosome | 6.51E-03 | 6 | P11215, P14598, Q71U36, Q13509, P68371, Q13488 | ITGAM, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1 | More | | Ranolazine | hsa04150 | mTOR signaling pathway | 2.23E-02 | 3 | P42338, Q13322, P49841 | PIK3CB, GRB10, GSK3B | More | | Ranolazine | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Ranolazine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | Ranolazine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Ranolazine | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Ranolazine | hsa04360 | Axon guidance | 4.39E-02 | 4 | P16333, P20827, O95631, P19174 | NCK1, EFNA1, NTN1, PLCG1 | More | | Ranolazine | hsa04371 | Apelin signaling pathway | 7.95E-04 | 7 | P62873, P63218, P50151, Q13370, Q14344, P84022, P0DP23 | GNB1, GNG5, GNG10, PDE3B, GNA13, SMAD3, CALM1 | More | | Ranolazine | hsa04380 | Osteoclast differentiation | 1.39E-03 | 8 | Q9UQC2, Q16539, P06239, P42338, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, LCK, PIK3CB, IL1R1, FCGR3B, TNF, LILRA2 | More | | Ranolazine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Ranolazine | hsa04540 | Gap junction | 1.08E-02 | 4 | Q13509, P68371, Q71U36, Q9NRA1 | TUBB3, TUBB2C, TUBA1A, PDGFC | More | | Ranolazine | hsa04610 | Complement and coagulation cascades | 4.69E-03 | 1 | P0C0L4 | C4A | More | | Ranolazine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Ranolazine | hsa04613 | Neutrophil extracellular trap formation | 4.09E-04 | 10 | P19174, P11215, P04908, Q93077, P62807, O60814, P68431, P14598, O43315, Q16539 | PLCG1, ITGAM, H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, AQP9, MAPK14 | More | | Ranolazine | hsa04621 | NOD-like receptor signaling pathway | 1.93E-02 | 8 | Q16539, P10599, Q9H1Y0, P43490, O00463, P01375, P09341, P12838 | MAPK14, TXN, ATG5, PBEF1, TRAF5, TNF, CXCL1, DEFA4 | More | | Ranolazine | hsa04623 | Cytosolic DNA-sensing pathway | 2.59E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Ranolazine | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | | Ranolazine | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | | Ranolazine | hsa04657 | IL-17 signaling pathway | 3.50E-06 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | Ranolazine | hsa04659 | Th17 cell differentiation | 1.30E-03 | 9 | P25963, P19174, P06239, P42224, P14784, P14778, P84022, P08238, P07766 | NFKBIA, PLCG1, LCK, STAT1, IL2RB, IL1R1, SMAD3, HSP90AB1, CD3E | More | | Ranolazine | hsa04662 | B cell receptor signaling pathway | 7.25E-03 | 4 | P49841, P42338, P21854, Q8N149 | GSK3B, PIK3CB, CD72, LILRA2 | More | | Ranolazine | hsa04664 | Fc epsilon RI signaling pathway | 7.09E-04 | 7 | P01375, P04141, Q16539, Q9UQC2, P07948, P19174, P09917 | TNF, CSF2, MAPK14, GAB2, LYN, PLCG1, ALOX5 | More | | Ranolazine | hsa04668 | TNF signaling pathway | 2.12E-03 | 7 | P01375, O00463, Q16539, P18848, P19875, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL2, BCL3, MMP9 | More | | Ranolazine | hsa04713 | Circadian entrainment | 2.18E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | | Ranolazine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Ranolazine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Ranolazine | hsa04724 | Glutamatergic synapse | 1.57E-02 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Ranolazine | hsa04726 | Serotonergic synapse | 3.80E-02 | 4 | P62873, P63218, P50151, P09917 | GNB1, GNG5, GNG10, ALOX5 | More | | Ranolazine | hsa04727 | GABAergic synapse | 4.18E-03 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Ranolazine | hsa04730 | Long-term depression | 6.53E-03 | 2 | Q14344, P07948 | GNA13, LYN | More | | Ranolazine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Ranolazine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Ranolazine | hsa04744 | Phototransduction | 6.93E-05 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Ranolazine | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.72E-02 | 3 | P14778, P42338, P24723 | IL1R1, PIK3CB, PRKCH | More | | Ranolazine | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Ranolazine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Ranolazine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Ranolazine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Ranolazine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Ranolazine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Ranolazine | hsa04929 | GnRH secretion | 3.63E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | Ranolazine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Ranolazine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Ranolazine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Ranolazine | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | | Ranolazine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Ranolazine | hsa04973 | Carbohydrate digestion and absorption | 4.12E-03 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Ranolazine | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Ranolazine | hsa05012 | Parkinson disease | 1.77E-02 | 6 | P60604, P19174, P0DP23, Q71U36, Q13509, P68371 | UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3, TUBB2C | More | | Ranolazine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Ranolazine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Ranolazine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Ranolazine | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | | Ranolazine | hsa05034 | Alcoholism | 2.90E-04 | 6 | P0DP23, P62873, Q93077, P62807, O60814, P68431 | CALM1, GNB1, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Ranolazine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.35E-04 | 8 | Q16539, P25963, Q13488, P09341, P19174, P25024, P25025, P07948 | MAPK14, NFKBIA, TCIRG1, CXCL1, PLCG1, CXCR1, CXCR2, LYN | More | | Ranolazine | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | | Ranolazine | hsa05132 | Salmonella infection | 2.75E-02 | 7 | P25963, P08238, O75369, Q71U36, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, FLNB, TUBA1A, TUBB3, TUBB2C, VPS41 | More | | Ranolazine | hsa05134 | Legionellosis | 4.75E-02 | 3 | P25963, P11215, P11142 | NFKBIA, ITGAM, HSPA8 | More | | Ranolazine | hsa05140 | Leishmaniasis | 3.20E-04 | 10 | P13612, O75015, P14598, P11215, P42224, P25963, P01375, P29350, P49006, Q16539 | ITGA4, FCGR3B, NCF1, ITGAM, STAT1, NFKBIA, TNF, PTPN6, MARCKSL1, MAPK14 | More | | Ranolazine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Ranolazine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Ranolazine | hsa05146 | Amoebiasis | 3.03E-03 | 8 | P09341, P19875, P14778, P27930, P01375, P05089, P30679, P22694 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, ARG1, GNA15, PRKACB | More | | Ranolazine | hsa05150 | Staphylococcus aureus infection | 4.36E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | Ranolazine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Ranolazine | hsa05163 | Human cytomegalovirus infection | 3.23E-05 | 14 | P01375, P25963, P62873, P63218, P50151, P0DP23, Q14344, P49841, P14778, P25025, Q16539, O00463, P30101, P01568 | TNF, NFKBIA, GNB1, GNG5, GNG10, CALM1, GNA13, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5, PDIA3, IFNA21 | More | | Ranolazine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 8.62E-05 | 10 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, LYN, CSF2, CALM1 | More | | Ranolazine | hsa05168 | Herpes simplex virus 1 infection | 3.79E-02 | 9 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, ZNF211, ZNF189 | More | | Ranolazine | hsa05170 | Human immunodeficiency virus 1 infection | 1.19E-02 | 8 | P62873, P63218, P50151, P0DP23, P30101, P01568, P25963, P19174 | GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21, NFKBIA, PLCG1 | More | | Ranolazine | hsa05200 | Pathways in cancer | 1.99E-03 | 15 | P08238, P42224, P25963, P19174, P43246, P84022, P20585, P62873, P63218, P50151, Q14344, O75293, P0DP23, P01568, P14784 | HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, MSH3, GNB1, GNG5, GNG10, GNA13, GADD45B, CALM1, IFNA21, IL2RB | More | | Ranolazine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Ranolazine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Ranolazine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Ranolazine | hsa05212 | Pancreatic cancer | 4.75E-02 | 3 | P42224, P84022, O75293 | STAT1, SMAD3, GADD45B | More | | Ranolazine | hsa05214 | Glioma | 4.44E-04 | 5 | P09619, P0DP23, Q02750, P19174, O75293 | PDGFRB, CALM1, MAP2K1, PLCG1, GADD45B | More | | Ranolazine | hsa05218 | Melanoma | 1.34E-02 | 2 | P09619, Q02750 | PDGFRB, MAP2K1 | More | | Ranolazine | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | | Ranolazine | hsa05230 | Central carbon metabolism in cancer | 4.10E-02 | 2 | P09619, Q02750 | PDGFRB, MAP2K1 | More | | Ranolazine | hsa05231 | Choline metabolism in cancer | 4.95E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | | Ranolazine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Ranolazine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Ranolazine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Ranolazine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | Ranolazine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Ranolazine | hsa05418 | Fluid shear stress and atherosclerosis | 1.29E-05 | 8 | Q16539, P42338, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, PIK3CB, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |